|Awarded On||August 18, 2021|
|Title||Overcoming Myeloma Resistance to Proteasome Inhibitors|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Qing Yi|
*Pending contract negotiation
Multiple myeloma (MM) is a bone cancer characterized by an accumulation of tumor cells in the bone marrow of patients. MM remains incurable despite large numbers of chemotherapy drugs available for patients. The major problem in the failure to cure MM patients is that patients will become resistant to all clinically used MM drugs, including traditional chemotherapeutics and novel agents. Even worse, some patients exhibit initial resistance and thus never respond to chemotherapy drugs, and most, if not all, MM patients who do respond will relapse after treatment and die from the disease. There is a class of chemotherapy drugs, namely proteasome inhibitors such as bortezomib (Btz) or carfilzom...